Current state · 2026.
The 2026 picture is a five-regulator divergence matrix overlaid with a partially harmonised E6(R3) substrate. The shifts below are operational, not theoretical — they affect dossier preparation today.
Current state, 2026.
What is live nowThe 2026 picture is a five-regulator divergence matrix overlaid with a partially harmonised E6(R3) substrate. The shifts below are operational, not theoretical — they affect dossier preparation today.
Step 4 reached, implementation rolling.
ICH E6(R3) Step 4 is the current global anchor, but regional implementation status should be verified on FDA, EMA, MHRA, PMDA, CDSCO, Health Canada, ANVISA, and other regulator pages before relying on a local requirement.
Transition window closed.
All ongoing EU trials under CTR 536/2014 from 31 Jan 2025. Single submission, Reporting MS / Concerned MS dynamics stabilising. Public disclosure (protocols, lay summaries, results) default with limited deferral. Midcap and academic sponsors under-resourced.
Divergence persists.
FDA, EMA/CTR/CTIS, CDSCO, PMDA, ANVISA, MHRA, Health Canada, and TGA all need jurisdiction-specific evidence maps. Timelines and portals should be checked from current official pages before operational planning.
FDA most predictable.
Submission clocks differ by product, phase, dossier quality, ethics pathway, questions received, and country procedure. Use current regulator pages and recent local experience before committing timelines.
Regulatory option, not experimental.
DCT and hybrid elements are now addressed in multiple regulator frameworks. Remote consent, telemedicine, home nursing, source-data access, and IMP shipment remain jurisdiction- and protocol-specific control questions.
Operational expectation.
FDA Diversity Action Plan expectations should be read against the current FDORA and FDA guidance status. Enrolment goals, rationale, and operational measures need programme-specific feasibility logic.
MDR Article 117 in force.
FDA 21 CFR 4 + PMOA-led IND or IND+IDE. EU: CTR medicinal portion + MDR Article 117 notified-body opinion for device-integral DDCs. CDSCO recognised but determination less codified. PMDA Combination Office. ANVISA RDC 751 + RDC 945 case-by-case.
Brazil is a jurisdiction to watch.
Brazil's 2024 clinical-research framework and ANVISA implementation changes make Brazil a jurisdiction to watch. Specific timelines, official submission systems, CONEP/CEP interaction, and DCT recognition should be checked against current ANVISA and official Brazilian sources before relying on them operationally.
India ICH trajectory.
India's NDCT 2019 framework, ICH Observer status, pharmacovigilance growth, and regulatory-capacity initiatives make India important to track. Full ICH Regulatory Member status should be described only when formally confirmed by ICH and CDSCO sources.
Single-IRB now common in US.
FDA local and central IRB pathways exist. EMA Part II remains national under CTR. India, Japan, and Brazil retain specific ethics-committee and local-review structures. Teams should verify current local registration, renewal, and submission requirements before site activation.
Frontier remains open.
Synthetic control arms in pivotals (case-by-case). AI/ML adaptive designs (ICH E20 traditional framework, AI-specific limited). In-silico trial evidence (mechanistic/device niche). Continuous submission models (pilot). Genomic-stratified ultra-rare (immature).
Friction, not convergence.
GDPR (EU), DPDP (India), LGPD (Brazil), HIPAA (US). DCT direct-to-participant IMP and telemedicine intersect three or four regimes per trial. Source-data verification across jurisdictions remains an inspection question.
Design-agnostic quality frame.
WHO Good Clinical Trials Practice 2024 frames quality without prescribing design. Useful for LMIC regulators bootstrapping frameworks. Listed Authority pathway parallel-tracks regulator maturity.
Official source register.
GCP / trial conduct anchorsGood Clinical Practice Step 4.
Official ICH E6(R3) Step 4 guideline. Use as the primary GCP anchor for participant protection, quality-by-design, sponsor oversight, and proportionality.
General considerations for clinical studies.
Official ICH E8(R1) guideline. Use for quality-by-design and critical-to-quality thinking before trial execution begins.
Estimands and sensitivity analysis.
Official ICH E9(R1) addendum. Use for aligning trial objectives, intercurrent events, estimands, and statistical interpretation.
Clinical electronic structured harmonised protocol.
Official FDA-hosted ICH M11 page. Use for structured protocol thinking and protocol information that can become more reusable across systems.
Clinical trials with decentralized elements.
FDA guidance page for decentralized trial elements. Use for remote visits, local healthcare providers, direct-to-participant processes, and oversight expectations.
Diversity Action Plans for clinical studies.
FDA guidance page for Diversity Action Plan expectations. Use for enrolment goals, rationale, and operational measures where applicable.
Regulation (EU) 536/2014 on clinical trials.
Official EUR-Lex anchor for the EU Clinical Trials Regulation. Use for EU authorisation, transparency, reporting, and trial-conduct context.
WHO guidance for best practices for clinical trials.
WHO 2024 clinical-trials best-practice guidance. Use for quality, relevance, ethics, and operational credibility across resource settings.